Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.

ABSTRACT:

Context

Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM).

Objective

The purpose of this study was to describe the effects of canagliflozin on bone fracture risk.

Design and setting

This was a randomized phase 3 study in patients with T2DM.

Patients and interventions

Canagliflozin doses of 100 and 300 mg were evaluated in the overall population of patients from 9 placebo- and active-controlled studies (N = 10 194), as well as in separate analyses of a single trial enriched with patients with a prior history/risk of cardiovascular disease (ie, the CANagliflozin cardioVascular Assessment Study [CANVAS]; N = 4327) and a pooled population of 8 non-CANVAS studies (N = 5867).

Outcome measures

The inc

SUBMITTER: Watts NB 

PROVIDER: S-EPMC4701850 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature